加载中
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
常规交易时段
US$10.2024
−US$0.3276 · -3.11%
盘中时间采用ET。市场数据可能有所延迟。
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
日内区间
当前US$10.2024
52周区间
当前US$10.2024
盘中时间采用ET。市场数据可能有所延迟。
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
日内区间
当前US$10.2024
52周区间
当前US$10.2024
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 18.17万 USD | 21.54万 USD | 20.46万 USD | 12.17万 USD | 7.8万 USD |
| 毛利 | −18.17万 USD | −21.54万 USD | −20.46万 USD | −12.17万 USD | −7.8万 USD |
| 研究与开发 | 575.75万 USD | 633.61万 USD | 1549万 USD | 2311.51万 USD | 1396.64万 USD |
| 销售、一般及管理费用 | 654.81万 USD | 409.87万 USD | 743.11万 USD | 771.24万 USD | 456.2万 USD |
| 营业费用 | 1230.56万 USD | 1043.48万 USD | 2271.65万 USD | 3082.75万 USD | 1852.83万 USD |
| 利息收入 | 18.02万 USD | 17.26万 USD | 46.33万 USD | 25.33万 USD | — |
| 利息支出 | — | — | — | 25.33万 USD | 243.16万 USD |
| 折旧和摊销 | 18.17万 USD | 21.54万 USD | 20.46万 USD | 12.17万 USD | 7.8万 USD |
| 营业利润 | −1248.73万 USD | −1065.02万 USD | −2292.11万 USD | −3094.93万 USD | −1860.63万 USD |
| 净利润 | −1249.43万 USD | −1078.48万 USD | −2245.79万 USD | −2799.12万 USD | −3021.28万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$35.00
上涨空间 243.06%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
